Fundz Deep Dive
Everything you need to win VitroScan — in one platform.
Who to reach, what to say, and why now on VitroScan — plus every funding round, exec hire, and M&A move that follows, each with the verified contact and the outreach written for you.
Get the full Deep Dive on VitroScan — free.
One free Deep Dive, emailed to you. No spam; unsubscribe anytime.
Ready now? Choose your plan · Request a demo · Sign in
Engage writes the reply
Grounded in signals no one else has — tuned to their persona.
Signals no one else has
UCC liens, benefit plans, 13F holdings, permits, exec moves — fused.
Verified contact + click-to-call
The decision-maker’s email and mobile — dial in-browser.
VitroScan secures funding from Biotech Booster program to deliver chemotherapy response prediction for ovarian cancer patients
Dec 02, 2024•over 1 year ago
Contract Type
partnership
LeidenBiotechnologyHealth CareDescription
VitroScan, a Leiden-based biotech company, announced that it has received funding from Biotech Booster to deliver chemotherapy response prediction for ovarian cancer patients. The funding will assist in preparing for clinical use and ensuring the service meets quality and regulatory standards for patients.
Agreement Insights
Based on industry dataStrategic partnership established
Partnership agreements typically involve technology integration and joint go-to-market strategies
Contract momentum indicator
Companies with recent agreements are 2.3x more likely to make additional purchases within 6 months